Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention VESALIUS-CV Subgroup Findings Reinforce Benefit of Earlier Initiation of Repatha in High-Risk Patients, with Median 44 mg/dL LDL-C Achieved THOUSAND OAKS, Calif., March...
Hence then, the article about repatha cuts risk of first major cardiovascular events by 31 in high risk patients without known significant atherosclerosis was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS )
Also on site :
- 1986 Rock Classic, Sparked by a Walk in the Rain, Left Singer in Tears the First Time He Heard It on the Radio
- Anthropologie’s ‘Dainty’ Crystal Heart Pendant Is a Romantic Coquette Layering Piece, Now Nearly 70% Off
- SpaceX stock falls back to earth shortly after Wall Street analysts release florid targets: ‘Paving the superhighway to the stars’